The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 10.00
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.50 (5.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Technology Venture Capital Funds Suffer Value Drop

Wed, 19th Oct 2016 11:05

LONDON (Alliance News) - Oxford Technology Management reported Wednesday a reduction in net asset value across all four of its London-listed venture capital funds in the first half of their financial years.

Oxford Technology VCT PLC reported its NAV per share reduced to 59.7 pence from 61.2p in the six months to August 31, as the fund's net assets dropped to GBP3.2 million at the end of the period, down from GBP3.3 million at February 29.

The fund reported a total NAV return per share of 113.7p in the six month period. The share price of the fund slipped to 38.0p at August 31 from 40.5p at February 29.

Shares in Oxford Technology VCT were untraded at 42.87p Wednesday.

Chairman Alex Starling noted over 85% of Oxford Technology VCT's net asset value is bound up in holdings in private company Select Technology Ltd and AIM-listed biotechnology company Scancell Holdings PLC. Starling said recent changes to qualification conditions for being a venture capital trust will not be an issue for the fund as it is not looking to invest in any new companies.

Oxford Technology 2 VCT PLC reported its NAV per share dipped to 28.0p from 28.2p over the six months to August 31, with net assets broadly flat at GBP1.9 million.

Total NAV return per share in the fund was 41.0p. The share price of Oxford Technology 2 rose to 22.0p at August 31 from 20.0p at February 29.

Shares in Oxford Technology VCT 2 were untraded at 18.43p Wednesday.

Oxford Technology VCT 3 PLC's NAV per share fell to 87.3p from 101.6p over the six months to August 31, as net assets declined to GBP5.9 million from GBP6.9 million.

The fund produced a total NAV return per share for the period of 119.3p. The share price of Oxford Technology 3 fell to 57.5p at August 31 from 62.5p at February 29.

Shares in Oxford Technology VCT 3 were untraded at 50.00p Wednesday.

Oxford Technology VCT 4 PLC reported its NAV per share declined slightly to 66.5p from 66.8p over the six months to August 31, with net assets broadly flat at GBP7.7 million. The fund's total NAV return per share for the period was 103.5p. The share price of Oxford Technology 4 fell to 47.0p at August 31 from 52.0p at February 29.

Shares in Oxford Technology VCT 4 were untraded at 45.0p Wednesday.

Oxford Technology VCT 4 Chairman David Livesley noted minor rises in the value of some of the fund's portfolio companies had been more than offset by a fall in the share price of Castleton Technology PLC over the period.

By Adam Clark; adamclark@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
27 Aug 2020 11:16

Scancell Consortium Gets Innovate UK Funding For Covid Vaccine Trial

Scancell Consortium Gets Innovate UK Funding For Covid Vaccine Trial

Read more
11 Aug 2020 16:18

Scancell Raises GBP15 Million To Fund Covid-19 Vaccine Development

Scancell Raises GBP15 Million To Fund Covid-19 Vaccine Development

Read more
22 Jul 2020 20:43

IN BRIEF: Scancell Secures GBP2 Million From Placing

IN BRIEF: Scancell Secures GBP2 Million From Placing

Read more
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.